BiotechTube

Tamoxifen + Placebo + Tamoxifen (open label)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bleeding

Conditions

Bleeding, Implants, Breakthrough Bleeding

Trial Timeline

Jan 20, 2017 → Jun 5, 2019

NCT ID
NCT02903121

About Tamoxifen + Placebo + Tamoxifen (open label)

Tamoxifen + Placebo + Tamoxifen (open label) is a approved stage product being developed by Merck for Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT02903121. Target conditions include Bleeding, Implants, Breakthrough Bleeding.

What happened to similar drugs?

11 of 20 similar drugs in Bleeding were approved

Approved (11) Terminated (2) Active (8)
✅Placebo + CurcuminMerckApproved
✅Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implantMerckApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved
✅Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)CSLApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02903121ApprovedCompleted

Competing Products

20 competing products in Bleeding

See all competitors
ProductCompanyStageHype Score
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/NDaiichi SankyoPhase 1
29
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
35
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
35
Elagolix + Estradiol /norethindrone acetate (E2/NETA)AbbViePhase 3
40
Risk of selected safety eventsAstraZenecaPre-clinical
26
AnticoagulantAstraZenecaPre-clinical
22
Esomeprazole Na + Cimetidine + Esomeprazole MgAstraZenecaPhase 3
40
Placebo + CurcuminMerckApproved
43
Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implantMerckApproved
39
Octreotide LAR DepotNovartisPhase 1
29
activated recombinant human factor VIINovo NordiskPre-clinical
26
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
eptacog alfa (activated) + placeboNovo NordiskPhase 3
32
activated recombinant human factor VII + activated recombinant human factor VIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
autologous stored plateletsNovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29